Polymer derivative of macrolide immunosuppressant
US10945997B2 · kind B2 · utility
0Cited by
5References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 19, 2016 |
| Grant date | Mar 16, 2021 |
| Priority date | — |
| Expiry date | Jul 27, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC08G69/48
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An object of the invention is to obtain a preparation which shows enhanced effectiveness and safety compared to tacrolimus, has the concentration in blood maintained at a constant level without individual differences, whereby the control of the amount of administration depending on the blood kinetics (blood trough concentration) becomes unnecessary. The present invention relates to a polymeric derivative of tacrolimus, in which a polyethylene glycol segment and an alcoholic hydroxy group of tacrolimus are bonded to side-chain carboxy groups of a polyaspartic acid derivative.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.